tbuckley/cabot-search huggingface dataset:
542P Long-term outcomes of neoadjuvant toripalimab with or without celecoxib in patients with dMMR/MSI-H locally advanced colorectal cancer: 3-month treatment cohort of the randomized phase II PICC trial
Authors: H. Hu, J. Zhang, X. Xie, L. Shi, Y. Cai, W. Li, Y. Xie, Z. Wu, G. Qin, J. Li, Y. Deng
Journal: Annals of Oncology (2024)
446MO SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma
Authors: W. Li, Z. Kang, F. Chen, S. Li, B. Zhang, M. Huang, X. Yang, F. She, S. Xiang, G. Liu, M. Liu
Journal: Annals of Oncology (2024)
528P The randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): 1-year follow-up updated data from JCOG2014 (ROBiTS)
Authors: Y. Suwa, H. Satake, K. Yamazaki, T. Tsushima, Y. Ishizuka, S. Boku, A. Takashima, T. Yamaguchi, M. Asayama, M. Yokota, K. Numata, T. Ohta, H. Yasui, Y. Kito, Y. Takii, M. Yokoyama, Y. Sano, H. Fukuda, T. Hamaguchi, Y. Kanemitsu
Journal: Annals of Oncology (2024)
505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Authors: S. Siena, K. Yamaguchi, J.C. Ruffinelli Rodriguez, E. Corral de la Fuente, Y. Kuboki, C. Cremolini, I. Victoria Ruiz, M.E. Elez Fernandez, J.H. Strickler, M. Furqan, B. Bashir, C. Nduka, J. Hippenmeyer, E. Chan, C. Xia, T. Masuishi
Journal: Annals of Oncology (2024)
520P Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
Authors: R. Garcia-Carbonero, N.A. Dasari, C. Eng, J. Tabernero, T. Yoshino, H. Hochster, D. Arnold, V. Randrian, W. Schelman, L. Dong, Z. Yu, L. Chen, S. Lonardi
Journal: Annals of Oncology (2024)
816MO Two hematological precursors and their impact on hematological malignancies
Authors: N.J. Boddicker, R. Griffin, E.G. Franke, S. Achenbach, K. Rabe, J.E. Olson, D.R. Obrien, A.D. Norman, T. Ma, T.G. Call, M. Hoel, E. Braggio, P.J. Hampel, C.A. Hanson, J.R. Cerhan, C. Vachon, S.A. Parikh, T.D. Shanafelt, S.L. Slager
Journal: Annals of Oncology (2024)
1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716
Authors: J.J. Luke, P.A. Ascierto, M.A. Khattak, P. Rutkowski, M. Del Vecchio, F. Spagnolo, J. Mackiewicz, L. de la Cruz Merino, V. Chiarion Sileni, J.M. Kirkwood, C. Robert, D. Schadendorf, F. De Galitiis, M.S. Carlino, A. Odeleye-Ajakaye, M. Kalabis, C. Krepler, A.M.M. Eggermont, G.V. Long
Journal: Annals of Oncology (2024)
1218P FALCONS, a non-interventional retrospective study in resected NSCLC patients using the EPITHOR database, first analysis
Authors: M. Wislez, M. Alifano, S. Michiels, H. Lena, L. Emonnot, C. Esnault, S. Gally, L. Goncalves, C. Kuypers, V. Machuron, S. Micon, S. Saget, K. Thokagevistk, L. Boyer, M. Dahan, P.A. Thomas
Journal: Annals of Oncology (2024)
1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
Authors: M. De Miguel, N. yamamoto, J. Raimbourg, B.C. Cho, M. Gottfried, S.M. Stemmer, J.W. Goldman, M.E. Blaney, T. Jennaro, A. Vasilopoulos, R.R. Li, K.J. Freise, M.R. Neagu Aristide, G. Morrison-Thiele, Z.N. Hunter, M. Burns, D.R. Camidge
Journal: Annals of Oncology (2024)
869P Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Authors: J. Fayette, C. Cropet, J. Gautier, C. Toullec, M. Vinches, M. Burgy, M. Iacob, M-C. Kaminsky-Forrett, S. Salas, B. Linot, A. Champagnac, I. Sondarjee, A. Pechery, D. Perol, J. Bourhis
Journal: Annals of Oncology (2024)
441O A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)
Authors: B. Neyns, I. Dirven, L. Lescrauwaet, M. Cammaert, W. Geens, X. Geeraerts, L. Stevens, S. Brock, M. Kockx, H. Everaert, A-M. Van Binst, S. Tuyaerts, J. Duerinck
Journal: Annals of Oncology (2024)
1073TiP A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
Authors: T.C. Hernandez Guerrero, B. Doger de Spéville, J. Yachnin, K.S. Rohrberg, M. Borggren, P. Holmkvist, I. Karlsson, M. Meller, L. Mårtensson, J-A. Nilsson, M. Vaapil, M. Chisamore, J.E. Wallin, I. Teige, B. Frendeus, A. McAllister
Journal: Annals of Oncology (2024)
482P The prognostic impact of CDKN2A/B heterozygous deletions in meningioma: Insights of a multicenter analysis
Authors: F.M. Ippen, T. Hielscher, A. Patel, K. Göbel, D. Friedel, S. Maas, A. von Deimling, W. Wick, A. Suwala, F. Sahm
Journal: Annals of Oncology (2024)
847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial
Authors: C. Hu, F. Xue, D. Ou, C. Xie, S. Lin, J. Li, X. Chen, F. Zhang, H. Ying, X. Lu, C. Shen, T. Xu, X. Ou, W. Li, X. Zhou, C. Du, X. He
Journal: Annals of Oncology (2024)
1214P Imaging AI prognosis of early stage lung cancer using CT radiomics
Authors: A. Valter, T. Kordemets, A. Gasimova, B. Heames, N. Waterfield Price, G. Hodgkinson, T. Vanakesa, I. Almre, L. Freitag, D.P. Carbone, K. Oselin
Journal: Annals of Oncology (2024)
454P Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Authors: J.M. Sepúlveda, M. Alonso, G. Velilla, C. Garcia Grove, M. Martínez-García, P. Foro, C. Garcia Gonzalez, C. Muriel Lopez, R. Luque, N. Luque, A. Stradella, P. Sàbat Viltró, M. Navarro Martín, B. Rivas López, M. Guzmán, E. Tovar-Ambel, G. Velasco, R. Sanchez Morillas, J. Fuster Salva
Journal: Annals of Oncology (2024)
1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
Authors: A. Nuccio, F. Salomone, G. Viscardi, F.M. Venanzi, A. Bulotta, F.R. Ogliari, S. Oresti, S.T. Riva, L. Mollica, M.G. Viganò, F. Passaretti, M. Ravasi, L. Papotto, M. Ferrara, B. Ricciuti, G. Veronesi, T. Cascone, M.C. Garassino, V. Torri, R. Ferrara
Journal: Annals of Oncology (2024)
1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
Authors: R. Dummer, A. Daud, T.K. Eigentler, T.R.J. Evans, J. Henry, F.S. Hodi, W.H. Miller, C. Robert, S. Saibil, L. Tachiki, M. Nayeri, B. Xing, J.M. Mehnert
Journal: Annals of Oncology (2024)
1057P Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysis
Authors: S. D'Ambrosio, F. Salomone, F. Vitale, A. Avanzo, A. Viggiano, L. Liguori, F. Napolitano, A. Santaniello, L. Formisano, R. Bianco, A. Servetto
Journal: Annals of Oncology (2024)
1217P B cell infiltration and memory TOX+ CD8+ T cells in stage I-II non-small cell lung cancer (NSCLC) predict response to neoadjuvant pembrolizumab: A phase I study
Authors: J. Bar, N. Maimon, Y. Glantzspiegel, I. Kamer, O. Zadok, E. Ofek, I. Daniel-Meshulam, D. Urban, A. Ackerstein, S.N. Daher, H. Gantz Sorotsky, A. Onn, N. Zeitlin, R.Y. Kremer, I. Redinsky, I. Gat-Viks, L. Keren
Journal: Annals of Oncology (2024)
1075TiP A phase I trial of ATG-101, an investigational PD-L1×4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN
Authors: J. Xue, J. Wen, J. Xiong, Y. Sun, J. Zhao, Y. Guo
Journal: Annals of Oncology (2024)
504O IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort
Authors: C. de la Fouchardiere, A. Zaanan, R. Cohen, S.M. Le Sourd, D. Tougeron, E. Soularue, O. Dubreuil, N. Williet, E. Samalin-Scalzi, G. Piessen, V. Hautefeuille, M. Jary, M. Ben Abdelghani, L. Evesque, P. Rochigneux, E. Blanc, F. Bibeau, A. DeMontfort, C. Coutzac
Journal: Annals of Oncology (2024)
849O Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: Results from the MYTHOS trial
Authors: I. Kinoshita, S. Kano, Y. Honma, N. Kiyota, M. Tahara, S. Takahashi, Y. Ito, Y. Hatanaka, Y. Matsuno, H. Dosaka-Akita
Journal: Annals of Oncology (2024)
1195P Whole-body magnetic resonance imaging (WB-MRI) screening in Li Fraumeni syndrome for early cancer diagnosis: The SIGNIFIED project
Authors: E. Cojocaru, A. Sohaib, S. Withey, S. Sardo-Infirri, C. Bunce, C. Clarke, J.Y. Weng, E. Scurr, R. Lee, R. Eeles, A. George
Journal: Annals of Oncology (2024)
508MO Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial
Authors: S. Ben Dhia, N. Barbet, T. Pace-Loscos, R. Schiappa, J.P. Gerard, L. Mineur, A.S. Dhadda, A. Sun Myint, J. Doyen
Journal: Annals of Oncology (2024)
541P Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Authors: T. André, S. Lonardi, H.J. Lenz, L.H. Jensen, E. Van Cutsem, Y. Touchefeu, R. Garcia-Carbonero, D. Tougeron, G.A. Mendez, M. Schenker, C. de la Fouchardiere, M.L. Limon, T. Yoshino, J. Li, J.L. Manzano Mozo, E. Cela, T. Chen, M. Lei, L. Jin, M.E. Elez Fernandez
Journal: Annals of Oncology (2024)
1197P Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer
Authors: D. Robbrecht, E. Koedoot, D. van der Meer, L.J. Ceton, T. Sijsenaar, W. Vader, L. Steinbusch, C. Steendam, J. Boormans, P.B. Ottevanger
Journal: Annals of Oncology (2024)
1207MO Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase II POTENTIAL study
Authors: Y. Tsutani, Y. Sakairi, N. Ikeda, Y. Tanaka, M. Tsuboi, H. Ito, K. Suzuki, K. Kushitani, K. Aokage, K. Yoshimura, K. Awai, G. Ishii, Y. Takeshima, M. Okada
Journal: Annals of Oncology (2024)
1216P Adjuvant pembrolizumab therapy for completely resected stage I NSCLC with micropapillary or solid histological subtype
Authors: S-H. Lee, Y. Bang, S. Park, H-A. Jung, J-M. Sun, J.S. Ahn, M-J. Ahn, Y. Jeon, J. Lee, J.H. Cho, H.K. Kim, Y.S. Choi, Y.M. Shim, Y-L. Choi, J. Han, J. Kim
Journal: Annals of Oncology (2024)
510MO Long-term survival and organ preservation with pembrolizumab in localized MSI-H/dMMR solid tumors
Authors: K. Ludford, M. LaPelusa, W. QIAO, J. Thomas, N. You, S. Thirumurthi, D. Maru, B. Iorgulescu, S. Kopetz, M.J. Overman
Journal: Annals of Oncology (2024)
1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
Authors: J. Reuss, C.H. Leung, S. Rosner, N. Zhou, A. Weissferdt, A. Pataer, W. Nassib William Junior, J. Taube, S. Broderick, J.D. Spicer, D.R. Jones, D. Gibbons, J.V. Heymach, V. Anagnostou, H. Lin, J.J. Lee, B. Sepesi, J. Chaft, P.M. Forde, T. Cascone
Journal: Annals of Oncology (2024)
1192P Optimizing lung cancer screening: Independent verification of an AI/ML computer-aided detection and characterization software as medical device
Authors: S. Bodard, C.M. Voyton, P. Baudot, E. Geremia, P-H. Siot, G. De Bie, V.K. Le, D. Francis, B. Renoust, B. Huet
Journal: Annals of Oncology (2024)
1203P Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Authors: G. Malagoli Tagliazucchi, W. Gong, M. Ghildiyal, M. Chavez, K. Nobuta, E. Sayyari, S. Truong, T. Vang, M. Yaylaoglu, G. Kim, Q. Bui, D. Spencer, S. Kim, J. Bernd, E. De Feo, S. Comer
Journal: Annals of Oncology (2024)
781P Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups
Authors: F. Marmé, F. Hilpert, M.K. Welslau, J.P. Grabowski, A. Schneeweiss, A.D. Hartkopf, S. Becker, D. Bauerschlag, P.A. Fasching, C. Brandi, J-K. Rehbein, R.M. Glowik, J. Sehouli
Journal: Annals of Oncology (2024)
1220P A phase III randomized trial investigating preventive effects of perioperative landiolol, a selective beta1 blocker, on the reduction of recurrence of completely resected NSCLC
Authors: Y. Hida, J. Suzuki, M. Endo, M. akahama, T. Kato, A. Iyoda, A. Watanabe, H. Kato, H. Ito, T. Murakawa, T. Nakagawa, H. Adachi, M. Mikubo, K. Asakura, M. Minami, T. Kawabata, H. Yamamoto, N. Horie, M. Sato
Journal: Annals of Oncology (2024)
575P Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
Authors: A. Hendifar, J. Gong, D.R. Spigel, A. Basu-Mallick, A. Espinosa, J.G. Misleh, D. Richards, J. Boles, M. Fakih, A.S. Paulson, K. Chung, A. Cohn, M. Gupta, K. Johnson, N. Bechar, K.A. Hoffman, S. Spector, M. Szarek, R. Wasserman, L.S. Rosen
Journal: Annals of Oncology (2024)
788P Pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Authors: N. Ngoi, J-Y. Lee, D. Lim, Y.L. Thian, Y.W. Lim, J.J. Chan, W.Y. Chay, Z. Zhang, A. Gopinathan, S.E. Lim, J. Low, J. Ng, P. Tong, Y.J. Lee, J. Park, J-W. Kim, J. Zhu, B.C. Tai, B-G. Kim, D.S. Tan
Journal: Annals of Oncology (2024)
854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial
Authors: Y. Tao, A. Auperin, X. Sun, X. Liem, C. Sire, L. Martin, Y. Pointreau, C. Borel, M-C. Kaminsky-Forrett, J. Miroir, F. Rolland, A. Coutte, F. Clatot, L. Sinigaglia, J. Thariat, C. Even, E.B. Saada, J. Guigay, J. Bourhis
Journal: Annals of Oncology (2024)
1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Authors: H. Wakelee, M. Reck, E. Felip, N.K. Altorki, E. Vallieres, R. Liersch, S. Oizumi, H. Tanaka, J.T. Hamm, S. McCune, E. Bennett, B.J. Gitlitz, V.A. McNally, S. Novello, M. Ballinger, W. Zou, B. Nabet, M. Srivastava, C. Zhou
Journal: Annals of Oncology (2024)
826P Efficacy of non-doxorubicin based regimens in severely G6PD deficient patients with DLBCL
Authors: S. Prem Sudha, F.S. Al-Ali, N.M. Abdelfattah, A.A. Shehata, A.S.A. Rashed, C. Ozturk, M. Venkatesan, R.H. Ibrahim, T.E. Najeebi
Journal: Annals of Oncology (2024)
1238TiP Combining immunotherapy with Trop2 ADc in early stage non-small cell lung cancer (CITADEL)
Authors: S.C.M. Li, T.S.K. Mok, C. Ng, A.H. Cheung, S. Chan, V.W.K. Lee, M.Y.F. Lim, J.C-H. Chow, K.M. Cheung, K. Li, G. Liao, I.W.C. Wong, V.H.F. Lee, S.T.F. Mok, K. Mok, R. Lau, J.W.Y. Chan, S.F. Nyaw
Journal: Annals of Oncology (2024)
1255MO A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Authors: Y-L. Wu, Z. Wang, Y. Cheng, J. Fang, X. Meng, Y. Pan, H. Zhao, Y. Zhao, H. Su, M. Sun, T. Zhou, P. Duan, D. Lv, Y. Wang, Y. Du, W. Zuo, P. Zhang, T. Zhang
Journal: Annals of Oncology (2024)
571P Neoadjuvant chemotherapy with FOLFIRINOX and short course radiotherapy in locally advanced rectal caner (ISANOX): A prospective phase II trial
Authors: F. Letaief-Ksontini, A. Mokrani, Y. Zenzri, H. Ben Mansour, A. Yousfi, F. Saadallah, R. dhouib, B.S. Azza, M. Ayadi, N. Chraiet, H. Rais, F. Chebbi, B. Sami, C. Nasr, A. Ben Mammar, A. Zidi, L. Charfi, M. Kacem, K. Meddeb, A. Mezlini
Journal: Annals of Oncology (2024)
1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment
Authors: M. Mckean, A.M. Weise, K.P. Papadopoulos, J.P. Crown, S.S. Thomas, J.M. Mehnert, J. Kaczmar, K.B. Kim, N.J. Lakhani, M.L. Yushak, J. Mani, F. Fang, L. Brennan, I. Lowy, M.E. Salvati, M.G. Fury, K. Lewis, O. Hamid
Journal: Annals of Oncology (2024)
1224P Evaluation of safety and feasibility of adjuvant chemotherapy in elderly patients with primary non-small cell lung cancer
Authors: A. Mogenet, Y. Vincent, F. Enoch, V. Pauly, A-L. Couderc, P. Tomasini, L. Greillier, J. Pluvy, X.B. d'Journo, A. Fourdrain, P.A. Thomas
Journal: Annals of Oncology (2024)
1082O KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma
Authors: G.V. Long, C. Robert, A.G. Hill, C. Gaudy Marqueste, D. Portnoy, R. Shapira, J.E. Cohen, M.A. Khattak, C. Lebbe, A.M. Menzies, G. Markel, G. Bar-Sela, W.H. Sharfman, C. Pages, O. Hamid, J.M. Mehnert, N. Jing, M. Kalabis, C. Krepler, R. Dummer
Journal: Annals of Oncology (2024)
1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors
Authors: E. Ellebaek, S. Khan, T.H. Borch, L.M. Guldbrandt, R.B. Friis, H. Schmidt, A.A. Luczak, C.H. Ruhlmann, L. Bastholt, I.M. Svane, M. Donia
Journal: Annals of Oncology (2024)
1420P Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Authors: S. Sato, S.L. Rhodes, Y. Aoki, I. Nakayama, T. Hashimoto, E. Finger, C-H. Chang, Y. Nakamura, A. Kawazoe, M. Saori, D. Kotani, Y. Kuboki, H. Bando, T. Kojima, R.E. Yanes, H. Honeycutt, I. Endo, N. Sakamoto, T. Yoshino, K. Shitara
Journal: Annals of Oncology (2024)
1089P Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
Authors: E. Burton, K. Wani, D. Milton, R. Lazcano, M. Tetzlaff, M.I. Ross, M.A. Postow, I.C. Glitza, M.K.K. Wong, S. Patel, M. Davies, J.E. Gershenwald, J. Mcquade, V. Prieto, C.E. Ariyan, J. Wargo, H.A. Tawbi, R.N. Amaria
Journal: Annals of Oncology (2024)
1231P Clinical characteristics and real-world treatment patterns in stage I-III resectable NSCLC: THASSOS-INTL study
Authors: K. Prabhash, R. Moor, T. Goksel, S.F. Nyaw, A.K. Altwairgi, F.J. Gonzalez Hernandez, E. Mohamed, P. Kantharaju, F. Sadek
Journal: Annals of Oncology (2024)
1076O Primary analysis of the EORTC 1208 Minitub trial: Prospective registry of sentinel node (SN) positive melanoma patients with minimal SN tumor burden
Authors: A.C.J. van Akkooi, D. Massi, M. Kicinski, P. Brackley, D. Gruenhagen, M. Rastrelli, M. Signh, H. Peach, B. Peric, C. Caracò, V. Boecxstaens, M. Moncrieff, S.I. Marreaud, R. Louis, G. de Schaetzen, S. Koljenovic, B. van de Wiel, M. Mandalà, M. Cook, A.M.M. Eggermont
Journal: Annals of Oncology (2024)
809MO Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
Authors: Y. Song, K. Zhou, S. Hou, Y. Zhang, F. Li, W. Yang, T. Yi, N. Lin, X. Liu, W. Meng, Z. Wang, Q. Lu, W. Tian, J. Zhu
Journal: Annals of Oncology (2024)
1213P Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial
Authors: F. Cappuzzo, C. Wang, W. Wang, H. Liu, Q. Chen, D. Yue, S. Wang, B. Yao, B. Barnes, G. Barnes
Journal: Annals of Oncology (2024)
1421P Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)
Authors: J. Tobias, M. Kundi, E. Garner-Spitzer, C.C. Zielinski, M. Maglakelidze, Z.G. Andric, Z. Petrovic, I.V. Nikolic, D. Ryspayeva, I.V. Bulat, R. Nagarkar, T. Chawla, L.O. Chong, B. Nixon, S. Yavrom, N.J. Ede, U. Wiedermann
Journal: Annals of Oncology (2024)
1422P First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2–) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2
Authors: F. Rivera Herrero, D-Y. Oh, K. Shitara, J-S. Chen, J. Jiang, S. Liu, Z. Dong, Q. Zhu, X. Zhang, B. Umiker, R. Kumar, S.Y. Rha, L. Shen
Journal: Annals of Oncology (2024)
1128P Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma
Authors: N.I. Khushalani, G. El-Haddad, K. Gage, M. Budzevich, M. Schell, E.G. Moros, C. Tichacek, W. Gibbons, R. Rogers, M. Nickels, L. Tetteh, Z. Eroglu, L. Karapetyan, A.S. Brohl, J. Markowitz, A. Tarhini, K. Hayes, L. Hazlehurst, M. McLaughlin, D. Morse
Journal: Annals of Oncology (2024)
1061P Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic review
Authors: F. Vitale, F. Salomone, S. D'Ambrosio, A. Avanzo, A. Viggiano, L. Liguori, F. Napolitano, A. Santaniello, L. Formisano, R. Bianco, A. Servetto
Journal: Annals of Oncology (2024)
1244P Association of tumor-draining lymph node metastatic patterns and neoadjuvant immunochemotherapy effectiveness in resectable non-small cell lung cancer
Authors: Y-H. Zhou, Z. Lin, Y. Zheng, Y. Lin, Z-R. Zhao, D-H. Liu, W-Y. Zhai, B-Y. Rao, S-C. Feng, H. Long
Journal: Annals of Oncology (2024)
1152P Correlation of biochemical secretion and imaging parameters on [18F]-SiTATE-PET/CT in pheochromocytoma and paraganglioma
Authors: M. Onkes, P. Dahlmann, J. Rübenthaler, M. Brendel, C. Schmid-Tannwald, T. Pfluger, L.M. Unterrainer, M. Kroiss, F. Völter
Journal: Annals of Oncology (2024)
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
Authors: E. Terán Brage, P. Reguera Puertas, E. Campaña-Díaz, M. Navarro Martín, P. Garcia Talavera, S. Rama Alonso, Á. López Gutiérrez, J. Roldan Ruiz, M.D.C. Garijo Martínez, D. Morchón Araujo, L. Posado-Domínguez, J.C. Redondo González, P. Díaz Sánchez, E. Pablo Martín, L.C. Felix, R. Lozano Mejorada, E. Fonseca Sánchez
Journal: Annals of Oncology (2024)
1114P Deciphering unresectable in-transit metastasis in melanoma: Multi-modal and longitudinal insights
Authors: G. Tarantino, A. Zaremba, T. Vallius, F. Rambow, L. Zimmer, A. Sucker, E. Livingstone, E. Hadaschik, R. Pelletier, Y. Shi, M. Lopez Leon, S. Makhzami, C. Lian, G. Murphy, P. Sorger, D. Liu, D. Schadendorf
Journal: Annals of Oncology (2024)
1117P Intratumoral microbiota is associated with prognosis in Chinese patients with skin melanoma
Authors: H. Jiang, B. Luo, X. Liu, F. Teng, D. Li, Y. Ding, X. Wen, Q-Y. Ding, L.B. Chen, J. Wu, Q. Zhang, Z. Chen, R. Li, X. Zhang, J. Li
Journal: Annals of Oncology (2024)
1198P Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Authors: P. Julien, D. Lu, J. Bieler, T. Zimmermann, E. Magrinelli, J. Wahl, A.C. Tuck, P. Krein
Journal: Annals of Oncology (2024)